Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMDX-2011P as a Retinal Tracer in Alzheimer's Disease
NCT06514001Phase 2Recruiting
- Sponsor
- Amydis
- Start
- Mar 2025
- Primary completion
- Jul 2027
- Modality
- Device-based Delivery, Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of AMDX-2011P in Alzheimer's disease (AD), sponsored by Amydis. Primary endpoint: Adverse Events Profile at 8 days. Started Mar 2025; status: recruiting.
02
Drugs
AMDX-2011P
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT06514001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06514001.